180 Wealth Advisors LLC Has $5.52 Million Position in Amgen Inc. $AMGN

180 Wealth Advisors LLC increased its stake in shares of Amgen Inc. (NASDAQ:AMGN) by 63.2% during the 4th quarter, Holdings Channel reports. The fund owned 16,870 shares of the medical research company’s stock after acquiring an additional 6,535 shares during the period. 180 Wealth Advisors LLC’s holdings in Amgen were worth $5,522,000 as of its most recent SEC filing.

A number of other large investors have also bought and sold shares of AMGN. Brighton Jones LLC grew its stake in Amgen by 23.5% in the fourth quarter. Brighton Jones LLC now owns 27,468 shares of the medical research company’s stock valued at $7,159,000 after acquiring an additional 5,226 shares during the period. Sivia Capital Partners LLC grew its position in Amgen by 10.6% in the 2nd quarter. Sivia Capital Partners LLC now owns 1,186 shares of the medical research company’s stock valued at $331,000 after purchasing an additional 114 shares during the period. Schnieders Capital Management LLC. grew its position in Amgen by 29.3% in the 2nd quarter. Schnieders Capital Management LLC. now owns 25,859 shares of the medical research company’s stock valued at $7,220,000 after purchasing an additional 5,853 shares during the period. Hillsdale Investment Management Inc. bought a new stake in Amgen during the 2nd quarter valued at $1,812,000. Finally, Evelyn Partners Investment Management LLP bought a new stake in Amgen during the 2nd quarter valued at $32,000. 76.50% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

AMGN has been the topic of a number of recent research reports. Sanford C. Bernstein lowered shares of Amgen from an “outperform” rating to a “market perform” rating and set a $335.00 price objective on the stock. in a research note on Tuesday, January 20th. Piper Sandler boosted their target price on shares of Amgen from $381.00 to $432.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 18th. BMO Capital Markets upped their target price on shares of Amgen from $335.00 to $372.00 and gave the stock an “outperform” rating in a report on Wednesday, December 3rd. Mizuho raised their price target on shares of Amgen from $280.00 to $295.00 and gave the company an “outperform” rating in a research report on Tuesday, February 10th. Finally, Royal Bank Of Canada lifted their price target on Amgen from $335.00 to $360.00 and gave the company an “outperform” rating in a research note on Wednesday, February 4th. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating, thirteen have given a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $354.60.

Amgen Stock Performance

AMGN stock opened at $347.80 on Monday. The company has a quick ratio of 0.90, a current ratio of 1.14 and a debt-to-equity ratio of 5.78. The firm has a market cap of $187.49 billion, a PE ratio of 24.44, a P/E/G ratio of 3.45 and a beta of 0.45. The business has a 50 day moving average of $360.29 and a 200-day moving average of $328.11. Amgen Inc. has a 12-month low of $261.43 and a 12-month high of $391.29.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings results on Tuesday, February 3rd. The medical research company reported $5.29 EPS for the quarter, topping analysts’ consensus estimates of $4.76 by $0.53. Amgen had a return on equity of 148.37% and a net margin of 20.98%.The business had revenue of $9.87 billion for the quarter, compared to analyst estimates of $9.46 billion. During the same period last year, the company posted $5.31 earnings per share. Amgen’s quarterly revenue was up 8.6% compared to the same quarter last year. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. As a group, sell-side analysts expect that Amgen Inc. will post 20.62 earnings per share for the current year.

Amgen Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, June 5th. Stockholders of record on Friday, May 15th will be paid a dividend of $2.52 per share. This represents a $10.08 dividend on an annualized basis and a dividend yield of 2.9%. The ex-dividend date is Friday, May 15th. Amgen’s payout ratio is presently 70.84%.

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.